Best Life Sciences Companies in Milano, Italy
The 31 best Life Sciences companies in Milano, Italy in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AAVantgarde Bio.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Milano
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AAVantgarde Bio Developer of gene therapies using Adeno-Associated Viral vectors | $206M | 12 mo ago | — | Alberto Auricchio Founder | GSAPMicrosoft ClarityGoogle Analytics+15 | — | — |
| 2 | Innovheart Provider of aesthetic devices for the treatment of atrioventricular valve diseases | $79M | 57 mo ago | 32 | Giovanni Righini Founder & CTO | WordPressMySQLPHP+16 | 144 patents Heart valve prostheses and associated implantation and crimping delivery systems | — |
| 3 | Genespire Developer of transformative gene therapies for people affected by genetic diseases | $69M | 25 mo ago | 10 | — | WordPressPleskMySQL+11 | 13 patents Lentiviral vector manufacturing and gene‑therapy delivery technologies | — |
| 4 | Enthera Developer of biotherapeutics for treating auto-immune disorders and type-1 diabetes | $46M | 69 mo ago | 15 | Gabriella Camboni Co-Founder | WordPressPleskMySQL+8 | 39 patents Therapeutic antibodies targeting TMEM219 and CD248 proteins for disease treatment | — |
| 5 | Empatica Developer of a wrist band to monitor physiological signals 64Tech top 23%Product top 34%Funding top 35%Growth top 35% All 11 signals ▾Techtop 23% Producttop 34% Fundingtop 35% Growthtop 35% Talenttop 38% Markettop 42% Moatbottom 44% Innovationbottom 43% Globalbottom 43% Customersbottom 41% Patentsbottom 38% Tech: 49 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Product: 5 published apps (41.5k installs) · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 64/100 | $31M | 47 mo ago | 133 | Melih Sadi Founder & Owner | SanityApple iCloud MailGoogle Workspace+23 | 2 patents Wearable electrodermal (skin conductance) sensors with current‑compensation circuitry | — |
| 6 | BetaGlue Technologies Provider of a radiotherapy platform for the treatment of solid tumors | $19M | 29 mo ago | 14 | — | WordPressMySQLPHP+18 | — | — |
| 7 | Nephris Developer of therapies for chronic kidney disease in diabetic patients | $3M | 54 mo ago | — | Paolo Fiorina Co-Founder | — | — | — |
| 8 | Naicons Developer of bioactive compounds for drug-resistant bacterial infections | $3M | 66 mo ago | — | Ermenegildo Beghe Director & CFO | Founder | — | 23 patents Patents concentrated in health & consumer products | — |
| 9 | MolMed Developer of gene and cell therapies for the treatment of cancer and rare diseases | $2M | 118 mo ago | 223 | — | — | — | — |
| 10 | Tensive Prostheses for a natural breast reconstruction | $2M | 21 mo ago | 18 | Valentina Morigi Co-founder and CFO | — | 23 patents Biodegradable 3D implant matrices for tissue engineering and breast reconstruction, minimizing foreign-body response. | — |
| 11 | PinCell Developer of anti-inflammatory therapy for the treatment skin diseases | $2M | 78 mo ago | 6 | Carlo Pincelli Co-Founder & CMO | — | 6 patents Therapeutic anti-Fas ligand antibodies for treating Stevens-Johnson/toxic epidermal necrolysis | — |
| 12 | Lipogems Developer of a disposable sterile device for orthopedic purposes | $2M | 52 mo ago | 21 | Carl Llewellyn CEO | WordPressMySQLPHP+17 | — | — |
| 13 | MgShell Developer of an intraocular device for drug delivery | $536K | 18 mo ago | 4 | Matteo Cereda Co-Founder | — | — | — |
| 14 | Heaxel Developer of a smart neurorehabilitation system | $111K | 80 mo ago | 18 | — | — | — | — |
Top 12 Life Sciences companies in Milano
#1
Series B · Milano, Umbria · founded 2021$206.2Mraised▾
Developer of gene therapies using Adeno-Associated Viral vectors. It has two proprietary platforms leveraging DNA recombination and protein-intein fusion, to deliver large genes for various therapeutic applications. It offers two lead programs Usher syndrome type 1B associated with retinitis pigmentosa , using dual hybrid platform and for Stargardt disease, using AAV antgarde Intein-mediated platform.
- Nov 2025Series B$141M
- Jun 2023Series A$65.2M
- Jul 2021Seed—
#2
Series B · Milano, Umbria · founded 2019 · 10 employees$69.3Mraised▾
Developer of transformative gene therapies for people affected by genetic diseases. The company's lead product includes GENE 101 for X-linked HIGM syndrome. Other candidates include GENE 102, 201, and 202 for inherited metabolic diseases.
- Sep 2024Series B$52M
- Apr 2020Series A$17.3M
#3
Series A · Milano, Umbria · founded 2012 · 18 employees$2.1Mraised▾
Tensive, a spin-off of Fondazione Filarete, is a biomedical company focused on developing innovative prostheses to provide for a natural breast reconstruction or augmentation. Its product is in laboratory testing phase and is not yet tested on humans. Tensive’s technology aims to stimulate the regeneration of natural fat. Its prostheses, not yet tested on humans, are based on synthetic and biodegradable biomaterials which are designed to be gradually degraded and replaced by the patient’s fat tissue once the regeneration is complete.
- Jan 2025Series A$14.6M
- May 2021Grant (prize money)$61K
- Jun 2018Grant (prize money)$2.2M
- Jan 2017Grant (prize money)$53.5K
#4
Series A · Milano, Umbria · founded 2019 · 4 employees$535.9Kraised▾
Developer of an intraocular device for drug delivery
- Apr 2025Series A$1.3M
- Feb 2023Seed$535.9K
#5
Series A · Milano, Umbria · founded 2017 · 14 employees$18.9Mraised▾
Provider of a radiotherapy platform for the treatment of solid tumors. The company is involved in developing a proprietary medical device platform, and a proprietary drug delivery system. The medical device platform is based on the combination of radioactive glue, β-emitting radiotherapy, and external beam radiation therapy which is administered to patients suffering from several types of cancers.
- Jun 2024Series A$8.7M
- Jul 2022Series A$10.2M
#6
Series B · Milano, Umbria · founded 2011 · 133 employees$30.9Mraised▾
Developer of a wristband to monitor physiological signals. The E4 wristband for researchers measures blood volume pulse, electrodermal activity, skin temperature and activity. It also offers Embrace, a wristband to monitor physiological stress, arousal, sleep and physical activity which provides seizure monitoring.
- Nov 2022Series B—
- Aug 2022Series B$25.9M
- Apr 2021Grant (prize money)$353.1K
- Mar 2021Grant (prize money)$115.9K
#7
Series C · Milano, Umbria · founded 2015 · 32 employees$78.7Mraised▾
Provider of aesthetic devices for the treatment of atrioventricular valve diseases. The company has developed a novel solution for mitral valve replacement. The device helps to manage structural stabilization, low LVOT, obstruction risk, and low risk of SAM.
- Jan 2022Series C$55M
- Aug 2020Series B$23.7M
- 2015Series A—
#8
Series A · Milano, Umbria · founded 2016 · 15 employees$45.9Mraised▾
Enthera develops biotherapeutics for treating auto-immune disorders. The pipelined products will be IGFBP3/TMEM219, a novel stem cell apoptosis pathway involved in the development and progression of several autoimmune conditions. The proprietary discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway.
- Jan 2021Series A$8.5M
- Jul 2020Series A$32.8M
- May 2018Seed$4.6M
#9
Seed · Milano, Umbria · founded 2021$3.2Mraised▾
Developer of therapies for chronic kidney disease in diabetic patients. The company focuses on the research and development of effective therapies in diabetic nephropathy that, can improve kidney function.
- Apr 2022Seed$3.2M
#10
Funding Raised · Milano, Umbria · founded 2013$2.9Mraised▾
Developer of bioactive compounds for drug-resistant bacterial infections. Thee company has proprietary platform called "micro4all," which serves as a search-and-order molecules engine accessible via an online subscription. It consists mainly of actinomycetes, the source of structurally diverse compounds with applications in human and veterinary medicine.
- May 2021Grant (prize money)$521.6K
- Mar 2021Grant (prize money)$314.9K
- Jan 2021Grant (prize money)$320.7K
- Jan 2018Grant (prize money)$310K
#11
Seed · Milano, Umbria · founded 2012 · 21 employees$1.8Mraised▾
Developer of a disposable sterile device for orthopedic purposes. They have developed a platform, LIPOGEMS, which enables single-step processing of lipoaspirates. It is used to harvest and transfer a patient’s own fat for the repair, reconstruction, and replacement of injured or damaged tissue.
- Jun 2022Seed$1.8M
#12
Acquired · Milano, Umbria · founded 2008 · 6 employees$1.8Mraised▾
Pincell develops anti-inflammatory therapy for the treatment of skin diseases. It provides treatments for different dermatological disorders particularly chronic inflammatory “orphan diseases” of the skin. They have developed the drug by targeting pathways involved in the pathomechanism.
- May 2020Seed$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Italy
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,095 Italy-affiliated papers.
- University of Milan77
- University of Naples Federico II54
- University of Padua51
- University of Bologna49
- University of Bari Aldo Moro48
- Gene3→16
- Transcription (linguistics)1→7
- DNA damage3→8
- Mitochondrion1→5
- Phosphorylation1→4
- Antimicrobial1→15
- Quality (philosophy)1→15
- Antioxidant1→13
- Crop2→14
- Fermentation1→13
- Agriculture2→15
- Antibiotic resistance1→14
- Food safety2→12
- Sustainability1→8
- Livestock1→6
Where biotechnology is researched across Italy
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.